Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + BYL719 + IMRT in Stage III/IVB HNSCC
NCT02282371Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2014
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alpelisib in head and neck squamous cell carcinoma (HNSCC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Phase II-recommended dose of BYL719 at 2 years. Started Oct 2014; status: completed.
02
Drugs
alpelisib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02282371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02282371.